全文获取类型
收费全文 | 29936篇 |
免费 | 2136篇 |
国内免费 | 146篇 |
专业分类
耳鼻咽喉 | 93篇 |
儿科学 | 1668篇 |
妇产科学 | 676篇 |
基础医学 | 2756篇 |
口腔科学 | 118篇 |
临床医学 | 3011篇 |
内科学 | 9477篇 |
皮肤病学 | 503篇 |
神经病学 | 2357篇 |
特种医学 | 263篇 |
外科学 | 3234篇 |
综合类 | 695篇 |
现状与发展 | 1篇 |
一般理论 | 6篇 |
预防医学 | 2637篇 |
眼科学 | 1042篇 |
药学 | 1249篇 |
2篇 | |
中国医学 | 61篇 |
肿瘤学 | 2369篇 |
出版年
2024年 | 44篇 |
2023年 | 280篇 |
2022年 | 261篇 |
2021年 | 396篇 |
2020年 | 372篇 |
2019年 | 149篇 |
2018年 | 554篇 |
2017年 | 564篇 |
2016年 | 649篇 |
2015年 | 637篇 |
2014年 | 533篇 |
2013年 | 845篇 |
2012年 | 2389篇 |
2011年 | 2653篇 |
2010年 | 921篇 |
2009年 | 895篇 |
2008年 | 2766篇 |
2007年 | 2642篇 |
2006年 | 2281篇 |
2005年 | 2396篇 |
2004年 | 2422篇 |
2003年 | 2531篇 |
2002年 | 1959篇 |
2001年 | 1444篇 |
2000年 | 327篇 |
1999年 | 170篇 |
1998年 | 232篇 |
1997年 | 142篇 |
1996年 | 111篇 |
1995年 | 66篇 |
1994年 | 82篇 |
1993年 | 43篇 |
1992年 | 46篇 |
1991年 | 36篇 |
1990年 | 42篇 |
1989年 | 38篇 |
1988年 | 41篇 |
1987年 | 39篇 |
1986年 | 33篇 |
1985年 | 27篇 |
1984年 | 25篇 |
1983年 | 15篇 |
1982年 | 21篇 |
1981年 | 24篇 |
1980年 | 13篇 |
1979年 | 9篇 |
1978年 | 10篇 |
1975年 | 7篇 |
1974年 | 6篇 |
1970年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
82.
Cecilia Nakid-Cordero Sylvain Choquet Nicolas Gauthier Noureddine Balegroune Nadine Tarantino Véronique Morel Nadia Arzouk Sonia Burrel Géraldine Rousseau Frédéric Charlotte Martin Larsen Vincent Vieillard Brigitte Autran Véronique Leblond Amélie Guihot for the K-VIROGREF Study Group 《American journal of transplantation》2021,21(8):2846-2863
EBV-positive and EBV-negative posttransplant lymphoproliferative disorders (PTLDs) arise in different immunovirological contexts and might have distinct pathophysiologies. To examine this hypothesis, we conducted a multicentric prospective study with 56 EBV-positive and 39 EBV-negative PTLD patients of the K-VIROGREF cohort, recruited at PTLD diagnosis and before treatment (2013–2019), and compared them to PTLD-free Transplant Controls (TC, n = 21). We measured absolute lymphocyte counts (n = 108), analyzed NK- and T cell phenotypes (n = 49 and 94), and performed EBV-specific functional assays (n = 16 and 42) by multiparameter flow cytometry and ELISpot-IFNγ assays (n = 50). EBV-negative PTLD patients, NK cells overexpressed Tim-3; the 2-year progression-free survival (PFS) was poorer in patients with a CD4 lymphopenia (CD4+<300 cells/mm3, p < .001). EBV-positive PTLD patients presented a profound NK-cell lymphopenia (median = 60 cells/mm3) and a high proportion of NK cells expressing PD-1 (vs. TC, p = .029) and apoptosis markers (vs. TC, p < .001). EBV-specific T cells of EBV-positive PTLD patients circulated in low proportions, showed immune exhaustion (p = .013 vs. TC) and poorly recognized the N-terminal portion of EBNA-3A viral protein. Altogether, this broad comparison of EBV-positive and EBV-negative PTLDs highlight distinct patterns of immunopathological mechanisms between these two diseases and provide new clues for immunotherapeutic strategies and PTLD prognosis. 相似文献
83.
Trevor A. Hart David M. Moore Syed W. Noor Nathan Lachowsky Daniel Grace Joseph Cox Shayna Skakoon-Sparling Jody Jollimore Abbie Parlette Allan Lal Herak Apelian Jordan M. Sang Darrell H. S. Tan Gilles Lambert the Engage Study Team 《Canadian journal of public health. Revue canadienne de santé publique》2021,112(6):1020
ObjectivesThe last Canadian biobehavioural surveillance study of HIV and other sexually transmitted and blood-borne infections (STBBI) among gay, bisexual and other men who have sex with men (GBM) was conducted in 2010. We designed a study to measure STBBI prevalence among GBM in metropolitan Montreal, Toronto and Vancouver and to document related preventive and risk behaviours.MethodsThe Engage Cohort Study used respondent-driven sampling (RDS) to recruit GBM who reported sex with another man in the past 6 months. At baseline, we examined recruitment characteristics of the samples, and the RDS-II-adjusted distributions of socio-demographics, laboratory-confirmed HIV and other STBBI prevalence, and related behaviours, with a focus on univariate differences among cities.ResultsA total of 2449 GBM were recruited from February 2017 to August 2019. HIV prevalence was lower in Montreal (14.2%) than in Toronto (22.2%) or Vancouver (20.4%). History of syphilis infection was similar across cities (14–16%). Vancouver had more HIV-negative/unknown participants who reported never being HIV tested (18.6%) than Toronto (12.9%) or Montreal (11.5%). Both Montreal (74.9%) and Vancouver (78.8%) had higher proportions of men who tested for another STBBI in the past 6 months than Toronto (67.4%). Vancouver had a higher proportion of men who used pre-exposure prophylaxis (PrEP) in the past 6 months (18.9%) than Toronto (11.1%) or Montreal (9.6%).ConclusionThe three largest cities of Canada differed in HIV prevalence, STBBI testing and PrEP use among GBM. Our findings also suggest the need for scale-up of both PrEP and STI testing among GBM in Canada. 相似文献
84.
A surveillance study of patterns of reirradiation practice using external beam radiotherapy in Japan
Hideya Yamazaki Gen Suzuki Norihiro Aibe Satoaki Nakamura Ken Yoshida Ryoongjin Oh JReRT Group 《Journal of radiation research》2021,62(2):285
The aim of this study was to survey the present status and patterns of reirradiation (Re-RT) practice using external beam radiotherapy in Japan. We distributed an e-mail questionnaire to the Japanese Society for Radiation Oncology partner institutions, which consisted of part 1 (number of Re-RT cases in 2008–2012 and 2013–2018) and part 2 (indications and treatment planning for Re-RT and eight case scenarios). Of the 85 institutions that replied to part 1, 75 (88%) performed Re-RTs. However, 59 of these 75 institutions (79%) reported difficulty in obtaining Re-RT case information from their databases. The responses from 37 institutions included the number of Re-RT cases, which totaled 508 in the period from 2009 to 2013 (institution median 3; 0–235), and an increase to 762 cases in the period from 2014 to 2018 (12.5; 0–295). A total of 47 physicians responded to part 2 of the survey. Important indications for Re-RT that were considered were age, performance status, life expectancy, absence of distant metastases and time interval since previous radiotherapy. In addition to clinical decision-making factors, previous total radiation dose, volume of irradiated tissue and the biologically equivalent dose were considered during Re-RT planning. From the eight site-specific scenarios presented to the respondents, >60% of radiation oncologists agreed to perform Re-RT. Re-RT cases have increased in number, and interest in Re-RT among radiation oncologists has increased recently due to advances in technology. However, several problems exist that emphasize the need for consensus building and the establishment of guidelines for practice and prospective evaluation. 相似文献
85.
Valentina Mazzotta Alessandro Cozzi Lepri Francesca Colavita Silvia Rosati Eleonora Lalle Claudia Cimaglia Jessica Paulicelli Ilaria Mastrorosa Serena Vita Lavinia Fabeni Alessandra Vergori Gaetano Maffongelli Fabrizio Carletti Simone Lanini Emanuela Caraffa Eugenia Milozzi Raffaella Libertone Pierluca Piselli Enrico Girardi AnnaRosa Garbuglia Francesco Vaia Fabrizio Maggi Emanuele Nicastri Andrea Antinori INMI COVID- Outpatient Treatment Study Group 《Journal of medical virology》2023,95(1):e28186
86.
Shun Kaneko Masayuki Kurosaki Toshie Mashiba Hiroyuki Marusawa Masahiko Kondo Yuji Kojima Yasushi Uchida Hideki Fujii Takehiro Akahane Hitoshi Yagisawa Atsunori Kusakabe Haruhiko Kobashi Takehiko Abe Hideo Yoshida Chikara Ogawa Koichiro Furuta Nobuharu Tamaki Keiji Tsuji Tomomichi Matsushita Namiki Izumi the Japanese Red Cross Liver Study Group 《Journal of medical virology》2023,95(1):e28210
Nucleos(t)ide analogs (NAs) cannot completely suppress the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study aimed to identify the risk factors for HCC development in naïve CHB patients treated with current NA. Patients receiving NA (n = 905) were recruited retrospectively from the 17 hospitals of the Japanese Red Cross Liver Study Group. All treatment-naïve patients had been receiving current NA continuously for more than 1 year until the end of the follow-up. We analyzed the accuracy of predictive risk score using the area under receiver operating characteristic curve. The albumin–bilirubin (ALBI) score was significantly improved by NA therapy (−0.171 ± 0.396; p < 0.001 at Week 48). A total of 72 (8.0%) patients developed HCC over a median follow-up of 6.2 (1.03–15.7) years. An independent predictive factor of HCC development was older age, cirrhosis, lower platelet counts at baseline and ALBI score, and alpha-fetoprotein (AFP) at 1 year after NA therapy according to multivariate analysis. The accuracy was assessed using the PAGE-B, mPAGE-B, aMAP, APA-B, and REAL-B scores that included these factors. Discrimination was generally acceptable for these models. aMAP and REAL-B demonstrated high discrimination with 0.866/0.862 and 0.833/0.859 for 3- and 5-year prediction from the status of 1 year after NA therapy, respectively. Baseline age and platelet count, as well as ALBI and AFP one year after NA, were useful for stratifying carcinogenesis risk. The aMAP and REAL-B scores were validated with high accuracy in Japanese CHB patients. 相似文献
87.
Lisanne E. de Koning Jessica Warnink-Kavelaars Marion A. van Rossum Diederik Bosman Leonie A. Menke Fransiska Malfait Rosa de Boer Jaap Oosterlaan Raoul H. H. Engelbert Lies Rombaut And the Pediatric Heritable Connective Tissue Disorders Study Group 《American journal of medical genetics. Part A》2023,191(7):1792-1803
The aim of the present study was to investigate the nature and prevalence of nonspecific somatic symptoms, pain and catastrophizing in children with Heritable Connective Tissue Disorders (HCTD), and to determine their association with disability. This observational, multicenter study included 127 children, aged 4–18 years, with Marfan syndrome (MFS) (59%), Loeys-Dietz syndrome (LDS) (8%), Ehlers-Danlos syndromes (EDS) (12%) and hypermobile Ehlers-Danlos syndrome (hEDS) (23%). The assessments included the Children's Somatization Inventory or parent proxy (CSI, PCSI), pain visual-analogue scale (VAS), SUPERKIDZ body diagram, Pain Catastrophizing Scale Child or parent proxy (PCS-C, PCS-P) and Childhood Health Assessment Questionnaire (CHAQ-30). Data from children aged ≥8 years were compared to normative data. In children ≥ 8 years (n = 90), pain was present in 59%, with a median of 4 (IQR = 3–9) pain areas. Compared to normative data, the HCTD group reported significantly higher on the CSI (p ≤ 0.001, d = 0.85), VAS pain intensity (p ≤ 0.001, d = 1.22) and CHAQ-30 (p ≤ 0.001, d = 1.16) and lower on the PCS-C (p = 0.017, d = −0.82) and PCS-P (p ≤ 0.001, d = −0.49). The intensity of nonspecific somatic symptoms and pain explained 45% of the variance in disability (r2 = 0.45 F(2,48) = 19.70, p ≤ 0.001). In children ≤ 7 years (n = 37), pain was present in 35% with a median of 5(IQR = 1–13) pain areas. The mean(SD) VAS scores for pain intensity was 1.5(2.9). Functional disability was moderately correlated to the number of pain areas (r = 0.56, p ≤ 0.001), intensity of nonspecific somatic symptoms (r = 0.63, p ≤ 0.001) and pain (r = 0.83, p ≤ 0.001). In conclusion, this study supports the need for comprehensive assessment of nonspecific somatic symptoms, pain, and disability in children with HCTD to allow tailored treatment. 相似文献
88.
89.
Verweij J.; Wanders J.; Nielsen A. L.; Pavlidis N.; Calabresi F.; Huinink W. ten Bokkel; Bruntsch U.; Piccart M.; Franklin H.; Kaye S. B.; On behalf of the EORTC Early Clinical Trials Group 《Annals of oncology》1994,5(4):375-376
PURPOSE:: To test the antitumor activity of Elsamitrucin in metastaticcancer of the breast, colon and rectum, non-small cell lungand ovary. PATIENTS AND METHODS:: Eligibility required histologically proven cancer. Patientswith colorectal or non-small cell lung cancer could not havereceived prior chemotherapy. Patients were entered if WHO PSwas 2 and organ functions were normal. Treatment consisted ofElsamitrucin 25 mg/m2/week given as a 510 min infusionfor at least 36 weekly doses. RESULTS:: One hundred and five patients entered the studies, 97 were eligible,94 are evaluable for toxicity and 75 for response. Toxicitymainly consisted of mild nausea/vomiting, and less frequentlyreversible hepatotoxicity and malaise. No objective responseswere seen. CONCLUSION:: Elsamitrucin at this dose and schedule is not an active drugin metastatic breast cancer, colorectal cancer, non-small celllung cancer or ovarian cancer. Elsamitrucin, phase II, breast, colorectum, nonsmall cell lung, ovary 相似文献
90.
Background: Effectiveness studies in natural family planning (NFP) published over the past 20 years have shown a wide range of contraceptive efficacy and acceptability. This seems to be due in part to different NFP methodologies. Consequently, we decided to carry out an effectiveness study in Europe to examine one group of the most widely spread NFP methods, the sympto-thermal methods.Methods: Between 1989 and 1995, 15 NFP groups from 10 European countries participated in a prospective European multicentre study. This paper reports on l328 women aged between 19 and 45 years and willing to participate for at least 12 cycles. Two types of symptothermal methods were mainly used, the symptothermal double-check methods (1046 women, 16 865 cycles of exposure, 34 unintended pregnancies) and the symptothermal single-check methods (214 women, 1495 cycles of exposure, 13 unintended pregnancies). The study was an observational study with prospectively collected data. The pregnancy rates, drop-out rates and lost-to-follow-up rates are presented separately for both subgroups according to the Kaplan–Meier method.Results: For the double-check methods, there was an unintended pregnancy rate of 2.6% at the end of the first 12 cycles of use (standard error or SE 0.55%), a drop-out rate for difficulties or dissatisfaction of 3.9% (SE 0.69%) and a lost-to-follow-up rate of 3.l% (SE 0.62%). In the single-check group, there was a total of 13 unintended pregnancies at the end of the first 12 cycles of study participation, giving an unintended pregnancy rate of 8.5% (SE 2.52%), a drop-out rate for difficulties or dissatisfaction of 3.0% (SE 1.76%) and a lost-to-follow-up rate of 23.4% (SE 4.35%). No pregnancy was observed in women over 40 years of age. Most pregnancies occurred because of deliberate unprotected intercourse in the fertile phase (user failure).Conclusions: The symptothermal double-check methods have proved to be effective family planning methods in Europe. The low drop-out-rate for difficulties or dissatisfaction with NFP shows the good acceptability. 相似文献